HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mathews, V. Articles by Chandy, M. Search for Related Content PubMed PubMed Citation Articles by Mathews, V. Articles by Chandy, M.

Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen

^* Department of Haematology, Christian Medical College, Vellore, India
^° Cytogenetics Unit, Christian Medical College, Vellore, India

Correspondence: Vikram Mathews, Department of Haematology, Christian Medical College, Vellore, 632004 India. Phone: international +91.416.2282891. Fax: international +91.416.2232035. E-mail: vikram{at}cmcvellore.ac.in

Ninety-eight newly diagnosed cases of PML-RARpositive APL were treated with a regimen of single agent ATO. FLT3 activating mutations were seen in 33% and an additional cytogenetic finding was noted in 23.2%. FLT3 activating mutations were significantly associated with a bcr3 PML-RARisoform (p=0.012) and a delay in achieving a molecular remission (p=0.022). Neither FLT3 activating mutations nor secondary cytogenetic changes had an impact on clinical outcome.

Key words: acute promyelocytic leukemia, arsenic trioxide, FLT3 mutation, cytogenetics.